Facing shrinking margins, OrderInsite is helping its community pharmacy customers address their most expensive line item and better their bottom line by up to 6% of their annual drug costs.
As we emerge from the pandemic, the expectation and demand for delivery of items, including prescriptions, will continue to grow. The technology is available to pharmacies. They just need to harness it. The ones that don’t will lose customers and revenue, and will ultimately be left behind.
With mounting challenges stacked on top of pharmacists who are already under water, how do we bring the profession back from the precipice? Technology to manage, monitor and master prescription drug inventory.
Pharmacies are no stranger to supply & demand issues, and now, in the midst of the vaccine rollout, the complexities are greater than ever. OrderInsite’s innovative and comprehensive technology solution helps pharmacies make informed decisions about their supply chain operations, with the added bonus of partnering with a company you can trust.
The CDC predicts a not-so-sunny future for public health this fall. Surprising? Not quite. However, retail pharmacies may be one of the few healthcare entities poised to weather the storm ahead.
In looking at parallels between COVID-19 and opioid abuse, two of the country’s most prominent public health emergencies in the last decade, there is a stark and alarming difference in the role data has played in how each crisis has unfolded and been addressed.
Already under a microscope for its role in proliferating America’s opioid crisis, it was unsurprising that AmerisourceBergen, one of the country’s largest drug wholesalers and distributors, made headlines again earlier this year when it settled with the California Board of Pharmacy over providing distributors and pharmacies with excessive quantities of pain medications.
Patients put an enormous amount of faith in pharmacists, landing the profession the fourth highest ranking in Gallup’s 2019 poll of professions Americans consider to be the most honest and ethical.
News of the $527 million judgement levied against Johnson and Johnson this past August for its role in proliferating the country’s opioid crisis marked a turning point in the epidemic which has been escalating in scope and notoriety for years.
Of all professional pursuits, doctor’s careers are especially fragile. Beyond the years of schooling, residency, and subsequent testing, providing patient care is an incredible responsibility that can be emotionally taxing. A misstep can mean the loss of one’s license, reputation, and potentially the end of their career.
